Takeda Pharmaceutical (TAK) Short-term Investments (2018 - 2026)

Takeda Pharmaceutical has reported Short-term Investments for 9 years, with the latest figure at $2.9 billion in Q2 2026.

• On a quarterly basis, Short-term Investments rose 24.7% year-over-year to $2.9 billion in Q2 2026; TTM through Jun 2026 was $2.9 billion, a 24.7% increase from a year earlier, with the FY2026 full-year figure at $2.8 billion, up 21.7% from the prior year.
• Short-term Investments was $2.9 billion for Q2 2026 at Takeda Pharmaceutical, up from $2.8 billion in the prior quarter.
• The five-year high for Short-term Investments was $2.9 billion in Q2 2026, with the low at $1.8 billion in Q3 2024.
• Average Short-term Investments over 5 years is $2.3 billion, with a median of $2.3 billion recorded in 2024.
• The largest YoY upside for Short-term Investments was 43.36% in 2024 against a maximum downside of 19.12% in 2024.
• Over 5 years, Short-term Investments stood at $1.9 billion in 2022, then slipped by 6.31% to $1.8 billion in 2023, then soared by 43.36% to $2.6 billion in 2024, then increased by 5.36% to $2.8 billion in 2025, then rose by 5.47% to $2.9 billion in 2026.
• The last three Short-term Investments figures came in at $2.9 billion (Q2 2026), $2.8 billion (Q1 2026), and $2.8 billion (Q4 2025), per Business Quant data.